Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238494 | 0.88 | LMNA (0.60) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL238493 | 0.88 | LMNA (0.60) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL10960204 | 0.79 | LMNA (0.74) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL10941399 | 0.79 | LMNA (0.74) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| Methandrostenolone SCHEMBL16755284 | 0.78 | LMNA (1.00) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| Methandrostenolone SCHEMBL8408550 | 0.78 | LMNA (1.00) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL5270893 | 0.78 | LMNA (0.81) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| Methandrostenolone SCHEMBL28423591 | 0.78 | LMNA (1.00) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| Methandrostenolone SCHEMBL21177905 | 0.78 | LMNA (1.00) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL10861103 | 0.78 | LMNA (0.81) | LMNAMAPTCYP19A1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163805-B2 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110135710-A1 | Methods and Compositions for the Inhibition of Gene Expression | PRONAI THERAPEUTICS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7932382-B2 | Amide substituted heterocylic compound; anticarcinogen; inducing apoptotic cell death, sensitizing cells to inducers of apoptosis | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-26 | — | — | US | disclosed |
| US-20110092452-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PANCREATIC CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-21 | — | — | US | disclosed |
| US-20090324587-A1 | Cancer Therapies and Pharmaceutical Compositions Used Therein | PRONAI THERAPEUTICS, INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324587-A1 | Cancer Therapies and Pharmaceutical Compositions Used Therein | RNASE1, TP53, RNMT | LMNA 3330/4885MAPT 3259/4885CYP19A1 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.